Treatment of rheumatoid arthritis by oral administration of bovine tracheal type II collagen

Rheumatology International

Volumn 20, Issue 4, 2001, Pages 138-144

  Ausar, S F ^a   Beltramo, D M ^a   Castagna, L F ^a   Quintana, S ^b   Silvera, E ^b   Kalayan, G ^b   Revigliono, M ^b   Landa, C A ^a   Bianco, I D ^a  

^a Centro de Excelencia en Productos y Procesos de Cordoba   (Argentina)

^b Hospital Zonal General Agudos San Roque   (Argentina)

Author keywords

Anticollagen antibodies; Autoimmunity; Clinical trial; Collagen type II; Oral tolerance

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; PLACEBO; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; AUTOIMMUNITY; CATTLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JOINT STIFFNESS; MALE; MORNING STIFFNESS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TRACHEA;

ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; ARTHRITIS, RHEUMATOID; CATTLE; COLLAGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; TRACHEA; TREATMENT OUTCOME;

EID: 0035030426     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002960100099     Document Type: Article

References (37)

1. 1. Eyre DR, Wu JJ, Woods PE, Weis MA (1991) The cartilage collagens and joint degeneration. Br J Rheumatol 30:10-15
2. 2. Trentham DE, Townes AS, Kand AH (1977) Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 146:857-868
3. 3. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. (1980) Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283:666-668
4. 4. Bradley DS, Nabozny GH, Cheng S, Zhou P, Griffiths MM, Luthra HS, David CS (1997) HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice. Implications in human rheumatoid arthritis. J Clin Invest 100:2227-2234
5. 5. Holmdahl R, Jansson L, Larsson A, Jonsson R (1990) Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand J Immunol 31:147-57
6. 6. Stuart JM, Watson WC, Kang AH (1988) Collagen autoimmunity and arthritis. FASEB J 2:2950-2956
7. 7. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM (1992) Induction of arthritis with monoclonal antibodies to collagen. J Immunol 148:2103-2108
8. 8. Ranges GE, Sriram S, Cooper SM (1985) Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 162:1105-1110
9. 9. Rönnelid J, Lysholm J, Engström-Laurent A, Klareskog L, Heyman B (1994) Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum 37: 1023-1029
10. 10. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P (1996) Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 39: 1720-1726
11. 125I-radioimmunoassay. Arthritis Rheum 26: 832-840
12. 12. Nagler-Anderson C, Bober, LA, Robinson ME, Siskind GW, Thorbecke J (1986) Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 83:7443-7446
13. 13. Thompson HSG, Harper N, Bevan DJ, Staines NA (1993) Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 16:189-199
14. 14. Weiner HL, Komagata Y (1998) Oral tolerance and the treatment of rheumatoid arthritis. Springer Semin Immunopathol 20:289-308
15. 15. Kalden JR, Sieper J (1998) Oral collagen in the treatment of rheumatoid arthritis. Arthritis Rheum 41:191-194
16. 16. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL (1993) Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-1730
17. 17. Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA (1996) Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 39:41-51
18. 18. Barnett ML, Combitchi D, Trentham DE (1996) A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 39:623-628
19. 19. Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE (1998) Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41:290-297
20. 20. Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS (1995) Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol 155:3653-3659
21. 21. McKown KM, Carbone LD, Kaplan SB, Aelion JA, Lohr KM, Cremer MA, Bustillo J, Gonzalez M, Kaeley G (1999) Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 42:1204-1208
22. 22. Steere EL, Somes GW, Myers LK, Seyer JM, Kang AH, Postlethwaite AE, Staines NA, Harper N, Ward FJ, Malmstrom V, Holmdahl R, Bansal S (1996) Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 103:368-375
23. 23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healy LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
24. 24. Felson, DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729-740
25. 25. Morgan K, Clague RB, Collins I, Ayad, S, Phinn SD, Holt PJL (1987) Incidence of antibodies to native and denatured cartilage collagens (types II, IX and XI) and to type I collagen in rheumatoid arthritis. Ann Rheum Dis 46:902-907
26. 26. Moreland LW, Heck LW, Koopman WJ (1997) Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum 40:397-409
27. 27. Kavanaugh AF (1998) Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 24:593-614
28. 28. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253-259
29. 29. Beckham JC, Caldwell DS, Peterson BL, Pippen AM, Currie MS, Keefe FJ, Weinberg JB (1992) Disease activity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 12:353-361
30. 30. Strobel S, Mcl. Mowat A (1998) Immune responses to dietary antigens: oral tolerance. Immunol Today 19:173-181
31. 31. Garside P, Steel M, Worthey EA, Satoskar A, Alexander J, Bluethmann H, Liew FY, Mowat AM (1995) T helper 2 cells are subject to high dose oral tolerance and are not essential for its induction. J Immunol 154:5649-5655
32. 32. Melamed D, Fishman-Lobell J, Uni Z, Weiner HL, Friedman A (1996) Peripheral tolerance of Th2 lymphocytes induced by continuous feeding of ovalbumin. Int Immunol 8:717-724
33. 2 and interleukin-1 production by human monocyte macrophages. FEBS Lett 198:208-212
34. 34. Charrière G, Hartmann DJ, Vignon E, Ronzière M-C, Herbage D, Ville G (1988) Antibodies to types I, II, IX and XI collagen in the serum of patients with rheumatic diseases. Arthritis Rheum 31:325-332
35. 35. Lu S, Holmdahl R (1999) Different therapeutic and bystander effects by intranasal administration of homologous type II and type IX collagens on the collagen-induced arthritis and pristane-induced arthritis in rats. Clin Immunol 90: 119-127
36. 36. Corthay A, Blacklund J, Broddefalk J, Michaelsson E, Goldsmith TJ, Kihlberg J, Holmdahl R (1998) Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 28:2580-2590
37. 37. Osman GE, Toda M, Kanagawa O, Hood LE (1993) Characterization of the T cell receptor repertoire causing collagen arthritis in mice. J Exp Med 177:387-395